N-acetylcysteine – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:47 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg N-acetylcysteine – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Acetylcysteine Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-acetylcysteine-market-2021-2025/ Tue, 08 Jun 2021 05:56:54 +0000 https://www.cri-report.com/?post_type=product&p=11761 In 2020, the sales value of Acetylcysteine increased by about 8.84% to CNY 1.016 billion in China.

The post Investigation Report on China’s Acetylcysteine Market 2021-2025 first appeared on CRI Report.

]]> Acetylcysteine, also known as N-acetylcysteine (NAC), is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with chronic bronchopulmonary disorders like pneumonia and bronchitis. Acetylcysteine was initially patented in 1960 and came into medical use in 1968. Its product, FLUIMUCIL was developed by Zambon Italia Srl. Acetylcysteine was approved in China in 2002. By the half-past of 2021, in addition to Zambon Italia Srl, there are more than 10 generic drug manufacturers in the Chinese Acetylcysteine market, such as Hangzhou Minsheng Pharmaceutical Co., Ltd., Hainan Star Pharmaceutical Co., Ltd., and Ruiyang Pharmaceutical Co., Ltd.

According to CRI analysis, the sales value of Acetylcysteine has grown rapidly from 2016 to 2019 in China, with the highest Year-on-Year growth rate of 47.93% in 2019. In 2020, the sales value of Acetylcysteine increased by about 8.84% to CNY 1.016 billion in China. The main reason is that the Covid-19 epidemic has affected the hospital’s overall diagnosis and treatment business, resulting in a decline in its growth rate. The CAGR of Acetylcysteine’s sales value in the Chinese market from 2016 to 2020 is 24.74%.

CRI predicts that the sales of Acetylcysteine in the Chinese market will have a restorative growth from 2021 to 2025 with the effective alleviation of the Covid-19 epidemic. In addition, Kangyuan Pharmaceutical submitted an application of Acetylcysteine solution for inhalation for marketing authorization on March 16 2021. It is expected that the price of acetylcysteine will decrease with the addition of new manufacturers. There is room for growth in both sales volume and sales.

Topics Covered:
-The impact of COVID-19 on China’s Acetylcysteine market
– Sales value of China’s Acetylcysteine 2016-2020
– Competitive landscape of China’s Acetylcysteine market
– Prices of Acetylcysteine in China
– Prices of Acetylcysteine in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Acetylcysteine market
– Prospect of China’s Acetylcysteine market from 2021 to 2025

The post Investigation Report on China’s Acetylcysteine Market 2021-2025 first appeared on CRI Report.

]]>